191 related articles for article (PubMed ID: 29852070)
1. Discovery of Highly Isoform Selective Orally Bioavailable Phosphoinositide 3-Kinase (PI3K)-γ Inhibitors.
Pemberton N; Mogemark M; Arlbrandt S; Bold P; Cox RJ; Gardelli C; Holden NS; Karabelas K; Karlsson J; Lever S; Li X; Lindmark H; Norberg M; Perry MWD; Petersen J; Rodrigo Blomqvist S; Thomas M; Tyrchan C; Westin Eriksson A; Zlatoidsky P; Öster L
J Med Chem; 2018 Jun; 61(12):5435-5441. PubMed ID: 29852070
[TBL] [Abstract][Full Text] [Related]
2. Design and Synthesis of a Novel Series of Orally Bioavailable, CNS-Penetrant, Isoform Selective Phosphoinositide 3-Kinase γ (PI3Kγ) Inhibitors with Potential for the Treatment of Multiple Sclerosis (MS).
Come JH; Collier PN; Henderson JA; Pierce AC; Davies RJ; Le Tiran A; O'Dowd H; Bandarage UK; Cao J; Deininger D; Grey R; Krueger EB; Lowe DB; Liang J; Liao Y; Messersmith D; Nanthakumar S; Sizensky E; Wang J; Xu J; Chin EY; Damagnez V; Doran JD; Dworakowski W; Griffith JP; Jacobs MD; Khare-Pandit S; Mahajan S; Moody CS; Aronov AM
J Med Chem; 2018 Jun; 61(12):5245-5256. PubMed ID: 29847724
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Highly Isoform Selective Thiazolopiperidine Inhibitors of Phosphoinositide 3-Kinase γ.
Collier PN; Messersmith D; Le Tiran A; Bandarage UK; Boucher C; Come J; Cottrell KM; Damagnez V; Doran JD; Griffith JP; Khare-Pandit S; Krueger EB; Ledeboer MW; Ledford B; Liao Y; Mahajan S; Moody CS; Roday S; Wang T; Xu J; Aronov AM
J Med Chem; 2015 Jul; 58(14):5684-8. PubMed ID: 26121481
[TBL] [Abstract][Full Text] [Related]
4. Design and Synthesis of Soluble and Cell-Permeable PI3Kδ Inhibitors for Long-Acting Inhaled Administration.
Perry MWD; Björhall K; Bonn B; Carlsson J; Chen Y; Eriksson A; Fredlund L; Hao H; Holden NS; Karabelas K; Lindmark H; Liu F; Pemberton N; Petersen J; Rodrigo Blomqvist S; Smith RW; Svensson T; Terstiege I; Tyrchan C; Yang W; Zhao S; Öster L
J Med Chem; 2017 Jun; 60(12):5057-5071. PubMed ID: 28520415
[TBL] [Abstract][Full Text] [Related]
5. Structure-based optimization leads to the discovery of NSC765844, a highly potent, less toxic and orally efficacious dual PI3K/mTOR inhibitor.
Han J; Chen Y; Yang C; Liu T; Wang M; Xu H; Zhang L; Zheng C; Song Y; Zhu J
Eur J Med Chem; 2016 Oct; 122():684-701. PubMed ID: 27448924
[TBL] [Abstract][Full Text] [Related]
6. Structure-Guided Discovery of Novel, Potent, and Orally Bioavailable Inhibitors of Lipoprotein-Associated Phospholipase A2.
Liu Q; Huang F; Yuan X; Wang K; Zou Y; Shen J; Xu Y
J Med Chem; 2017 Dec; 60(24):10231-10244. PubMed ID: 29193967
[TBL] [Abstract][Full Text] [Related]
7. A versatile high-throughput screen for inhibitors of lipid kinase activity: development of an immobilized phospholipid plate assay for phosphoinositide 3-kinase gamma.
Fuchikami K; Togame H; Sagara A; Satoh T; Gantner F; Bacon KB; Reinemer P
J Biomol Screen; 2002 Oct; 7(5):441-50. PubMed ID: 14599360
[TBL] [Abstract][Full Text] [Related]
8. Structure-based virtual screening approach to the discovery of phosphoinositide 3-kinase alpha inhibitors.
Park H; Choi H; Hong S; Kim D; Oh DS; Hong S
Bioorg Med Chem Lett; 2011 Apr; 21(7):2021-4. PubMed ID: 21354792
[TBL] [Abstract][Full Text] [Related]
9. Structure and ligand-based design of mTOR and PI3-kinase inhibitors leading to the clinical candidates VS-5584 (SB2343) and SB2602.
Poulsen A; Nagaraj H; Lee A; Blanchard S; Soh CK; Chen D; Wang H; Hart S; Goh KC; Dymock B; Williams M
J Chem Inf Model; 2014 Nov; 54(11):3238-50. PubMed ID: 25317974
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase γ inhibitors.
Leahy JW; Buhr CA; Johnson HW; Kim BG; Baik T; Cannoy J; Forsyth TP; Jeong JW; Lee MS; Ma S; Noson K; Wang L; Williams M; Nuss JM; Brooks E; Foster P; Goon L; Heald N; Holst C; Jaeger C; Lam S; Lougheed J; Nguyen L; Plonowski A; Song J; Stout T; Wu X; Yakes MF; Yu P; Zhang W; Lamb P; Raeber O
J Med Chem; 2012 Jun; 55(11):5467-82. PubMed ID: 22548342
[TBL] [Abstract][Full Text] [Related]
11. Structural basis for isoform selectivity in a class of benzothiazole inhibitors of phosphoinositide 3-kinase γ.
Collier PN; Martinez-Botella G; Cornebise M; Cottrell KM; Doran JD; Griffith JP; Mahajan S; Maltais F; Moody CS; Huck EP; Wang T; Aronov AM
J Med Chem; 2015 Jan; 58(1):517-21. PubMed ID: 24754609
[TBL] [Abstract][Full Text] [Related]
12. Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitors.
Hua Z; Bregman H; Buchanan JL; Chakka N; Guzman-Perez A; Gunaydin H; Huang X; Gu Y; Berry V; Liu J; Teffera Y; Huang L; Egge B; Emkey R; Mullady EL; Schneider S; Andrews PS; Acquaviva L; Dovey J; Mishra A; Newcomb J; Saffran D; Serafino R; Strathdee CA; Turci SM; Stanton M; Wilson C; Dimauro EF
J Med Chem; 2013 Dec; 56(24):10003-15. PubMed ID: 24294969
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Potent, Efficient, and Selective Inhibitors of Phosphoinositide 3-Kinase δ through a Deconstruction and Regrowth Approach.
Barton N; Convery M; Cooper AWJ; Down K; Hamblin JN; Inglis G; Peace S; Rowedder J; Rowland P; Taylor JA; Wellaway N
J Med Chem; 2018 Dec; 61(24):11061-11073. PubMed ID: 30532965
[TBL] [Abstract][Full Text] [Related]
14. From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors.
Liang J; Labadie S; Zhang B; Ortwine DF; Patel S; Vinogradova M; Kiefer JR; Mauer T; Gehling VS; Harmange JC; Cummings R; Lai T; Liao J; Zheng X; Liu Y; Gustafson A; Van der Porten E; Mao W; Liederer BM; Deshmukh G; An L; Ran Y; Classon M; Trojer P; Dragovich PS; Murray L
Bioorg Med Chem Lett; 2017 Jul; 27(13):2974-2981. PubMed ID: 28512031
[TBL] [Abstract][Full Text] [Related]
15. Fragment-Based Approach to the Development of an Orally Bioavailable Lactam Inhibitor of Lipoprotein-Associated Phospholipase A2 (Lp-PLA
Woolford AJ; Day PJ; Bénéton V; Berdini V; Coyle JE; Dudit Y; Grondin P; Huet P; Lee LY; Manas ES; McMenamin RL; Murray CW; Page LW; Patel VK; Potvain F; Rich SJ; Sang Y; Somers DO; Trottet L; Wan Z; Zhang X
J Med Chem; 2016 Dec; 59(23):10738-10749. PubMed ID: 27933945
[TBL] [Abstract][Full Text] [Related]
16. 6-Aryl substituted 4-(4-cyanomethyl) phenylamino quinazolines as a new class of isoform-selective PI3K-alpha inhibitors.
Yadav RR; Guru SK; Joshi P; Mahajan G; Mintoo MJ; Kumar V; Bharate SS; Mondhe DM; Vishwakarma RA; Bhushan S; Bharate SB
Eur J Med Chem; 2016 Oct; 122():731-743. PubMed ID: 27479483
[TBL] [Abstract][Full Text] [Related]
17. Optimization of Orally Bioavailable PI3Kδ Inhibitors and Identification of Vps34 as a Key Selectivity Target.
Henley ZA; Amour A; Barton N; Bantscheff M; Bergamini G; Bertrand SM; Convery M; Down K; Dümpelfeld B; Edwards CD; Grandi P; Gore PM; Keeling S; Livia S; Mallett D; Maxwell A; Price M; Rau C; Reinhard FBM; Rowedder J; Rowland P; Taylor JA; Thomas DA; Hessel EM; Hamblin JN
J Med Chem; 2020 Jan; 63(2):638-655. PubMed ID: 31855425
[TBL] [Abstract][Full Text] [Related]
18. Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinase.
Staben ST; Heffron TP; Sutherlin DP; Bhat SR; Castanedo GM; Chuckowree IS; Dotson J; Folkes AJ; Friedman LS; Lee L; Lesnick J; Lewis C; Murray JM; Nonomiya J; Olivero AG; Plise E; Pang J; Prior WW; Salphati L; Rouge L; Sampath D; Tsui V; Wan NC; Wang S; Weismann C; Wu P; Zhu BY
Bioorg Med Chem Lett; 2010 Oct; 20(20):6048-51. PubMed ID: 20822905
[TBL] [Abstract][Full Text] [Related]
19. Phosphoinositide 3-kinase gamma inhibition plays a crucial role in early steps of inflammation by blocking neutrophil recruitment.
Ferrandi C; Ardissone V; Ferro P; Rückle T; Zaratin P; Ammannati E; Hauben E; Rommel C; Cirillo R
J Pharmacol Exp Ther; 2007 Sep; 322(3):923-30. PubMed ID: 17526805
[TBL] [Abstract][Full Text] [Related]
20. p38 MAP kinase inhibitors. Part 5: discovery of an orally bio-available and highly efficacious compound based on the 7-amino-naphthyridone scaffold.
Natarajan SR; Liu L; Levorse M; Thompson JE; O'Neill EA; O'Keefe SJ; Vora KA; Cvetovich R; Chung JY; Carballo-Jane E; Visco DM
Bioorg Med Chem Lett; 2006 Oct; 16(20):5468-71. PubMed ID: 16945534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
